Thu, Mar 5, 2015, 10:44 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Navidea Biopharmaceuticals, Inc Message Board

noonangf1225 9 posts  |  Last Activity: Feb 27, 2015 8:02 AM Member since: Apr 17, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Macrophage Therapeutics, Inc., a subsidiary of Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), today announced the appointment of leading experts to a newly formed scientific advisory board (SAB) to serve as a strategic resource to Macrophage Therapeutics as it looks to develop therapeutic applications for Navidea’s innovative Manocept™ platform. The inaugural SAB consortium is comprised of world-renowned scientists and clinicians in the areas of oncology, immunology, autoimmune diseases and macrophage biology. The SAB will serve as an ongoing resource to provide management with counsel and guidance pertaining to the research, development, and clinical application of Manocept technology.

    [...] In order to ensure the most rapid development of products that address markets with large unmet medical needs, we are creating an advisory board committed to being actively engaged with management to evaluate and prioritize opportunities. The SAB is initially comprised of scientists who have had direct experience with our technology as well as prominent experts in the area of immunology. This board will be augmented with experts with specific therapeutic area expertise as potential applications grow,” said Michael Goldberg, M.D., Navidea Director and Macrophage Therapeutics Chief Executive Officer. “In addition, the previously announced INITIAL FUNDING for Macrophage Therapeutics is progressing towards CLOSING NEXT WEEK.”

  • Reply to

    Sold half my shares anticipating dilution

    by ryno1ryno Feb 20, 2015 11:43 AM
    noonangf1225 noonangf1225 Feb 20, 2015 4:21 PM Flag

    Get a life, you and your aliases.

  • The data, presented by Remco de Bree, M.D., Ph.D. head and neck surgeon from the VU University Medical Center, The Netherlands, included the following:

    Lymphoseek is uniquely suited to identify the sentinel lymph node where the injection site is in very close proximity
    Previously reported clinical trial data, which were used to obtain European approval in 2014 and which demonstrated a 2.56% false negative rate for sentinel lymph node detection compared to the gold standard of post-operative histopathology
    There was no observable difference in Lymphoseek performance when used either the day prior to or the day of surgery
    Lymphoseek displayed a favorable safety profile and delivered rapid and consistent injection site clearance and localization to sentinel nodes.
    “Not only was the detection rate of sentinel nodes by Lymphoseek high, but it has other advantages,” said Professor de Bree. “Where other tracers have problems in identifying and harvesting of sentinel nodes when there is a close spatial relation between injection site and sentinel node, which is pronounced in floor of mouth tumors, tilmanocept facilitated accurate prediction of the spread of the cancer in all oral cavity sites. With the recent approval of Lymphoseek, surgeons are no longer limited to en-bloc surgery of all the soft tissue in a lymph node region.”

  • noonangf1225 noonangf1225 Feb 17, 2015 10:20 AM Flag

    Message for Pup the Idiot: “Lymphoseek-guided pre- and intraoperative SLN detection can considerably reduce the number of subjects with oral cancer that require neck dissection, thus leading to a substantial reduction in surgical trauma with potential subsequent morbidity. Lymphoseek was specifically designed to provide clinicians reliable and accurate location of sentinel lymph nodes to aid effective cancer staging and inform post-surgical treatment. Thus, thousands of patients with oral cavity cancers may benefit from a less invasive procedure with accurate diagnostic evaluation of their condition,” said Michael Tomblyn, M.D., Navidea’s Executive Medical Director. “We are pleased that the published results from our NEO3-06 Phase 3 clinical trial demonstrating its utility and safety in identifying SLNs are now available to the patient and medical community.”

  • Reply to

    Best Practices

    by jesse.buck Jan 29, 2015 2:39 PM
    noonangf1225 noonangf1225 Jan 29, 2015 3:37 PM Flag

    We need that idiot Pup to get back on line again and tell us that there is no significant benefit with LS, etc... Predictably, he and his idiot minions will post.

  • Reply to

    Why... is the cash burn so high?

    by ryno1ryno Jan 16, 2015 3:24 PM
    noonangf1225 noonangf1225 Jan 17, 2015 11:53 AM Flag

    Stats say they have total cash of $26 million and total debt of $30 million. If correct that's very damned good compared to where they were.

  • Reply to

    Ryno the quaternary poster

    by barryjohannasan Jan 11, 2015 5:28 AM
    noonangf1225 noonangf1225 Jan 12, 2015 1:39 AM Flag

    IGNORE the idiots. Fools u are to give them print time.

  • noonangf1225 noonangf1225 Jan 6, 2015 4:21 PM Flag

    Ryno: you state/quote: "Navidea's effort to expand approval of Lymphoseek into head-and-neck cancer is meaningless because there are no outcomes data to support sentinel node biopsies in this cancer indication." What an incredibly stupid statement in the face of studies, FDA, etc. Just blatantly stuuuuuuupid.

  • I have read that LS is now approved for solid tumor. Is that ALL solid tumors, or just head and neck and breast and melanoma. Please, informed comments only.

NAVB
1.70+0.080(+4.94%)Mar 5 4:03 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Geron Corporation
NASDAQThu, Mar 5, 2015 4:00 PM EST
Orexigen Therapeutics, Inc.
NASDAQThu, Mar 5, 2015 4:00 PM EST
Orbital ATK, Inc.
NYSEThu, Mar 5, 2015 4:02 PM EST